Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Sutro Biopharma, Inc. (STRO)

7.1   -0.32 (-4.31%) 12-02 16:00
Open: 7.32 Pre. Close: 7.42
High: 7.575 Low: 6.83
Volume: 293,226 Market Cap: 408(M)

Technical analysis

as of: 2022-12-02 4:26:26 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 9.05     One year: 9.76
Support: Support1: 6.78    Support2: 5.64
Resistance: Resistance1: 7.75    Resistance2: 8.35
Pivot: 7.49
Moving Average: MA(5): 7.25     MA(20): 7.45
MA(100): 6.3     MA(250): 7.4
MACD: MACD(12,26): 0.1     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 30.9     %D(3): 29.7
RSI: RSI(14): 48.2
52-week: High: 16.6  Low: 3.32
Average Vol(K): 3-Month: 363 (K)  10-Days: 397 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ STRO ] has closed above bottom band by 15.7%. Bollinger Bands are 17% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.58 - 7.63 7.63 - 7.67
Low: 6.74 - 6.79 6.79 - 6.82
Close: 7.03 - 7.11 7.11 - 7.17

Company Description

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Headline News

Fri, 02 Dec 2022
Live Earth Products Celebrates World Soil Day by Keeping the Turf at the Rose Bowl Stadium as Strong as t - Benzinga

Wed, 30 Nov 2022
The Fresh Factory Reports Strong Q3 2022 Results with its Highest Ever Quarterly Revenue -

Wed, 30 Nov 2022
Rental hosts prepare for uncertainty ahead of short-term rental application deadline - FOX 5 San Diego

Thu, 24 Nov 2022
Nov. 30 Is Deadline for New Licenses for Short-Term Home Rentals in San Diego - Times of San Diego

Wed, 23 Nov 2022
Sutro Biopharma to Participate in Upcoming Investor Conferences - Sutro Biopharma (NASDAQ:STRO) - Benzinga

Fri, 18 Nov 2022
Should You Buy Sutro Biopharma Inc (STRO) in Biotechnology Industry? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 57 (M)
Shares Float 48 (M)
% Held by Insiders 5.6 (%)
% Held by Institutions 91.2 (%)
Shares Short 4,150 (K)
Shares Short P.Month 4,030 (K)

Stock Financials

EPS -2.48
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.19
Profit Margin (%) -175.9
Operating Margin (%) -164.3
Return on Assets (ttm) -18.6
Return on Equity (ttm) -47.9
Qtrly Rev. Growth 195.3
Gross Profit (p.s.) -0.74
Sales Per Share 1.21
EBITDA (p.s.) -1.9
Qtrly Earnings Growth 0
Operating Cash Flow 6 (M)
Levered Free Cash Flow -34 (M)

Stock Valuations

PE Ratio -2.88
PEG Ratio 0.1
Price to Book value 1.69
Price to Sales 5.84
Price to Cash Flow 70

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.